HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Consensus Recommendation of “Hold” from Brokerages

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has been given a consensus rating of “Hold” by the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $16.8750.

A number of brokerages have commented on HCM. Jefferies Financial Group raised shares of HUTCHMED to a “strong-buy” rating in a research note on Monday, January 19th. Wall Street Zen cut shares of HUTCHMED from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of HUTCHMED in a research report on Thursday, January 22nd. Finally, Bank of America reduced their price objective on HUTCHMED from $21.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, March 10th.

HUTCHMED Stock Up 0.1%

Shares of HCM opened at $14.16 on Friday. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.05. HUTCHMED has a 1 year low of $11.51 and a 1 year high of $19.50. The business’s 50 day simple moving average is $14.68 and its 200-day simple moving average is $14.84.

HUTCHMED (NASDAQ:HCM) last announced its quarterly earnings results on Thursday, March 5th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $2.50 by ($2.49). The company had revenue of $135.42 million for the quarter, compared to the consensus estimate of $290.50 million. Equities research analysts anticipate that HUTCHMED will post 0.16 EPS for the current year.

Hedge Funds Weigh In On HUTCHMED

Several large investors have recently modified their holdings of HCM. Tema Etfs LLC bought a new stake in HUTCHMED in the second quarter worth $641,000. XY Capital Ltd raised its stake in shares of HUTCHMED by 291.1% in the third quarter. XY Capital Ltd now owns 52,757 shares of the company’s stock valued at $831,000 after acquiring an additional 39,266 shares during the period. Vanguard Personalized Indexing Management LLC raised its stake in shares of HUTCHMED by 12.1% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,363 shares of the company’s stock valued at $273,000 after acquiring an additional 1,873 shares during the period. Blue Trust Inc. lifted its holdings in shares of HUTCHMED by 131.5% in the 4th quarter. Blue Trust Inc. now owns 7,708 shares of the company’s stock worth $103,000 after acquiring an additional 4,378 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of HUTCHMED by 1.2% in the 4th quarter. State Street Corp now owns 321,305 shares of the company’s stock worth $4,283,000 after acquiring an additional 3,801 shares during the last quarter. Institutional investors own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.